GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytori Cell Research Institute Inc (TSE:3750) » Definitions » Debt-to-Revenue

Cytori Cell Research Institute (TSE:3750) Debt-to-Revenue : 3.53 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Cytori Cell Research Institute Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Cytori Cell Research Institute's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円919 Mil. Cytori Cell Research Institute's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円6,843 Mil. Cytori Cell Research Institute's annualized Revenue for the quarter that ended in Dec. 2023 was 円2,196 Mil. Cytori Cell Research Institute's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 3.53.


Cytori Cell Research Institute Debt-to-Revenue Historical Data

The historical data trend for Cytori Cell Research Institute's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytori Cell Research Institute Debt-to-Revenue Chart

Cytori Cell Research Institute Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.70 7.43 6.15 6.94 3.97

Cytori Cell Research Institute Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.23 4.32 4.45 5.39 3.53

Competitive Comparison of Cytori Cell Research Institute's Debt-to-Revenue

For the Biotechnology subindustry, Cytori Cell Research Institute's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cytori Cell Research Institute's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytori Cell Research Institute's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Cytori Cell Research Institute's Debt-to-Revenue falls into.



Cytori Cell Research Institute Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Cytori Cell Research Institute's Debt-to-Revenue for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(901.237 + 7605.855) / 2144.712
=3.97

Cytori Cell Research Institute's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(918.765 + 6843.099) / 2196.232
=3.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


Cytori Cell Research Institute Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Cytori Cell Research Institute's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Cytori Cell Research Institute (TSE:3750) Business Description

Traded in Other Exchanges
N/A
Address
1-1-1 Otemachi, Otemachi Park Building, Chiyoda-ku, Tokyo, JPN, 100-0004
Cytori Cell Research Institute Inc developing a new clinical approach to cell therapy to provide better medical care to patients by providing medical care that responds to unmet medical needs based on innovative regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.

Cytori Cell Research Institute (TSE:3750) Headlines

No Headlines